Abexinostat

also known as PCI-24781 · Abexinostat hcl · ABEXINOSTAT HYDROCHLORIDE · CRA 024781 HYDROCHLORIDE · CRA 24781 HYDROCHLORIDE · CRA-024781 · CRA-024781 HCL · CRA-024781-01 · +6 more

Small molecule

Developed for: Hodgkins lymphoma · non-Hodgkin lymphoma · diffuse large B-cell lymphoma · follicular lymphoma · metastatic malignant neoplasm · plasma cell myeloma · anaplastic astrocytoma · anaplastic oligodendroglioma
+21 more
· chronic lymphocytic leukemia/small lymphocytic lymphoma · cutaneous melanoma · endometrioid adenocarcinoma · fallopian tube carcinoma · female breast carcinoma · gliosarcoma · head and neck squamous cell carcinoma · hematopoietic and lymphoid cell neoplasm · hormone receptor-positive breast cancer · leukemia · mantle cell lymphoma · metastatic melanoma · metastatic neoplasm · non-small cell lung carcinoma · ovarian carcinoma · primary peritoneal carcinoma · renal cell carcinoma · sarcoma · ureter cancer · urothelial carcinoma · uterine corpus cancer
Investigated by: Xynomic Pharmaceuticals, Inc. · Pharmacyclics LLC. · Pamela Munster · Brigham and Women's Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Dana-Farber Cancer Institute
+8 more
· GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease · Janssen Scientific Affairs, LLC · Massachusetts General Hospital · Memorial Sloan Kettering Cancer Center · Novartis · Pfizer · Rahul Aggarwal · University of Nebraska

Trials 15 · a red edge is where a trial was stopped

today NCT05698524 · Ph 1 NCT04498520 · Ph 1 NCT03934567 · Ph 2 NCT03936153 · Ph 2 NCT04024696 · Ph 1/2 NCT03939182 · Ph 1 NCT03600441 · Ph 2 NCT03590054 · Ph 1 NCT03592472 · Ph 3 NCT01543763 · Ph 1 NCT01149668 · Ph 1 NCT01027910 · Ph 1/2 NCT00724984 · Ph 1/2 NCT00562224 · Ph 1 NCT00473577 · Ph 1

200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 18 trials
Phase 1	NCT05698524	Jun 2023 → Jul 2027 expected	anaplastic astrocytoma, anaplastic oligodendroglioma, gliosarcoma	University of Nebraska	Recruiting	No outcome recorded
Phase 1	NCT04498520	Mar 2021 → Jun 2025	endometrioid adenocarcinoma, fallopian tube carcinoma, female breast carcinoma, hormone receptor-positive breast cancer +4	Pamela Munster	Withdrawn	No outcome recorded
Phase 1	NCT03939182	May 2019 → Apr 2025	diffuse large B-cell lymphoma, mantle cell lymphoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1	NCT03590054	Aug 2018 → Nov 2023	cutaneous melanoma, head and neck squamous cell carcinoma, metastatic malignant neoplasm, metastatic melanoma +3	Rahul Aggarwal	Completed	No outcome recorded
Phase 1	NCT01543763	Jun 2012 → Jan 2024	metastatic neoplasm	Pamela Munster	Completed	No outcome recorded
Phase 1	NCT01149668	Jun 2010 → Dec 2012	Hodgkins lymphoma, leukemia, non-Hodgkin lymphoma, plasma cell myeloma	Pharmacyclics LLC.	Completed	No outcome recorded
Phase 1	NCT00562224	Nov 2007 → Jun 2010	Hodgkins lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma	Pharmacyclics LLC.	Completed	No outcome recorded
Phase 1	NCT00473577	Aug 2005 → Nov 2007	hematopoietic and lymphoid cell neoplasm	Pharmacyclics LLC.	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT04024696	Jan 2020 → Dec 2024 overdue	non-Hodgkin lymphoma	Xynomic Pharmaceuticals, Inc.	Active not recruiting	No outcome recorded
Phase 1/2	NCT01027910	Feb 2009 → Mar 2015	sarcoma	Massachusetts General Hospital	Completed	No outcome recorded
Phase 1/2	NCT00724984	Jul 2008 → Nov 2012	Hodgkins lymphoma, non-Hodgkin lymphoma	Pharmacyclics LLC.	Completed	No outcome recorded
Phase 23 trials
Phase 2	NCT03934567	Apr 2020 → Jan 2025 overdue	follicular lymphoma	Xynomic Pharmaceuticals, Inc.	Active not recruiting	No outcome recorded
Phase 2	NCT03936153	Jan 2020 → Jul 2026 overdue	diffuse large B-cell lymphoma	Xynomic Pharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 2	NCT03600441	Aug 2018 → Dec 2027 expected	follicular lymphoma	Xynomic Pharmaceuticals, Inc.	Active not recruiting	No outcome recorded
Phase 31 trial
Phase 3	NCT03592472	Jul 2018 → Dec 2026 expected	renal cell carcinoma	Xynomic Pharmaceuticals, Inc.	Recruiting	No outcome recorded

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	Abexinostat	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03592472 ↗ 7 NCT03939182 ↗ NCT03590054 ↗ NCT03600441 ↗ NCT04024696 ↗ NCT04498520 ↗ NCT03936153 ↗ NCT03934567 ↗
Known as	Abexinostat hcl	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	ABEXINOSTAT HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	CRA 024781 HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	CRA 24781 HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	CRA-024781	“CRA-024781 is a novel, broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is...” PMID 16731764 ↗ May 2006
Known as	CRA-024781 HCL	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	CRA-024781-01	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	CRA-24781	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473577 ↗
Known as	PCI 24781 HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	PCI-24781	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00562224 ↗ 5 NCT01149668 ↗ NCT01027910 ↗ NCT01543763 ↗ NCT05698524 ↗ NCT00724984 ↗
Known as	PCI-24781-01	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	PZP115891	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01543763 ↗
Known as	S-78454	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Known as	S-78454-1	ChEMBL registry synonym — accepted as the source's own label CHEMBL2103863 ↗
Action	Inhibit	“Pan-histone Deacetylase (HDAC) Inhibitor” NCT01149668 ↗
Modality	Small molecule	— CHEMBL2103863 ↗
Route	Oral	“PCI-24781 orally at doses starting at 30 mg/m2” NCT00562224 ↗